A study suggests that serum NSE and lactate dehydrogenase (LDH) may serve as biomarkers for predicting efficacy and survival in patients with small-cell lung cancer receiving first-line platinum-based chemotherapy (Liu et al., 2017). Here, ENO2 is linked to small cell lung carcinoma.